Ionis Pharmaceuticals IONS Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's operating lease right-of-use asset amortization?
- Ionis Pharmaceuticals (IONS) reported operating lease right-of-use asset amortization of $3.49M in Q1 2026.
- How has Ionis Pharmaceuticals's operating lease right-of-use asset amortization changed year-over-year?
- Ionis Pharmaceuticals's operating lease right-of-use asset amortization increased by 34.7% year-over-year, from $2.59M to $3.49M.
- What is the long-term trend for Ionis Pharmaceuticals's operating lease right-of-use asset amortization?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's operating lease right-of-use asset amortization has grown at a 56.2% compound annual growth rate (CAGR), from $1.72M to $10.25M.